Participants with recurrent/metastatic disease that has recurred within 6 months of completing such treatment are considered eligible for study treatment. Adenocarcinoma of the prostate (PRC) 3.d.iii.a) Added: Participants with bone-only disease should have progression confirmed Modified the eligibility criteria to the requirements for target disease characteristics and for participants with UCC, CRC, PRC, and NSCLC. Revised Protocol No.: 04 Date: 31-May-2019 237 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Summary of key changes of Revised Protocol 01 Section Number & TitleDescription of Change Brief Rationale as per PCWG2 criteria and require confirmatory scans. 3.d.iv) Added: Participants must have received abiraterone and enzalutamide. Urothelial carcinoma (UCC) 3.e.iii) Removed: All participants must have measurable disease by CT or MRI per RECIST v1.1 criteria. 3.e.iv.1) Edited so that participants with UCC must have progression or recurrence after treatment with at least 1 platinum-containing chemotherapy regimen (if platinum eligible) but no more than 2 regimens for metastatic or surgically unresectable locally advanced urothelial cancer 3.e.v) Removed: Participants that have received more than 2 prior lines of chemotherapy must not have liver metastases. Section 7.3.2: BMS-986226 Dose-limiting Toxicities; Section 7.3.5: Exceptions to Permanent Discontinuation Criteria1) The following dose limiting toxicity (DLT) criteria were edited/added: Isolated Grade 3 fever not associated with hemodynamic compromise (eg, hypotension, clinical or laboratory evidence of impaired end-organ perfusion) or with other symptoms of infusion-related reactions that returns to ≤Grade 1 with standard treatment in ≤1 hour Grade 3 infusion reaction that returns to Grade 1 in ≤1 hour 2) The following DLT criterion has been added: Grade 4 rash of any duration 3) A 4-week DLT observation period for the Preliminary Safety Cohort was added. 4) Consideration to permanently discontinue study therapy, on a case-by-case basis, for participants with any severe Grade 3 drug-related adverse event (AE) that recurs was added to Section 7.3.5.Clarified specific requirements for DLT criteria, and modified the DLT requirements consistent with the introduction of preliminary safety cohort . Table 2-2: On-treatment Procedural Outline (CA021002); Section 3.3: Benefit/Risk Assessment; Table 7.1-1: Selection and Timing of Dose per PartInstructions were added for participants to be observed for at least 60 minutes following completion of BMS-986226 infusion.Extended the post-infusion observation period to monitor for potential infusion-related reactions. Revised Protocol No.: 04 Date: 31-May-2019 238 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Summary of key changes of Revised Protocol 01 Section Number & TitleDescription of Change Brief Rationale Table 2-2: On-treatment Procedural Outline (CA021002); Table 9.5-4: Additional and Retreatment Cycles Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226, Edits were made to the procedural outline table, pharmacokinetic and immunogenicity sample schedule table to clarify which procedures and sampling schedules are to be followed for additional cycles and that participants in Parts C1 and C2 are not eligible for additional cycles.Updated the study procedural outline table to align with the description of additional cycles in Section 5.1.4: Treatment with Additional Cycles beyond 24 Weeks. Table 2-2: On-treatment Procedural Outline (CA021002); Table 2-5: Retreatment and Extended Treatment Procedural Outline for Parts A, B1, B2, and B3 Only (CA021002); Table 9.5-4: Additional and Retreatment Cycles Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226, Edits were made to the procedural outline table, pharmacokinetic and immunogenicity sampling schedule table to clarify which procedures and sampling schedules are to be followed for retreatment cycles and that participants in Parts C1 and C2 are not eligible for extended treatment.Updated the study procedural outline tables to align with the description of retreatment in Section 5.1.5.1: Retreatment During Response Follow-up. Table 2-5: Retreatment and Extended Treatment Procedural Outline for Parts A, B1, B2, and B3 Edits were made to the procedural outline table to clarify which procedures are to be followed for extended treatment cycles and that participants in Parts C1 and C2 are not Updated the study procedural outline table to align with the description of extended Revised Protocol No.: 04 Date: 31-May-2019 239 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Summary of key changes of Revised Protocol 01 Section Number & TitleDescription of Change Brief Rationale Only (CA021002); Table 2-6: Retreatment and Extended Treatment Follow-up Procedural Outline (CA021002); Section 5.1.6: Extended Treatmenteligible for extended treatment. Section 5.1.6 was added.treatment in Section 5.1.6: Extended Treatment.